View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 13, 2021

Poseida and Takeda to develop non-viral in vivo gene therapy programmes

The companies will initially develop up to six gene therapies using Poseida’s technologies and other engineering platforms.

Poseida Therapeutics and Takeda Pharmaceutical have entered a research collaboration and license agreement to develop non-viral in vivo gene therapy programmes, including the former’s Hemophilia A programme.

Under the deal, the companies will research and develop up to eight in vivo gene therapy programmes.

Initially, they will develop up to six gene therapies using Poseida’s Cas-CLOVER, piggyBac, and biodegradable DNA and RNA nanoparticle technology, as well as other genetic engineering platforms.

Takeda Rare Diseases Drug Discovery Unit head Madhu Natarajan said: “Poseida’s differentiated platform technologies show great promise in developing non-viral in vivo gene therapies using their novel genetic engineering and delivery technologies that complement our existing collaborations.

“This partnership reinforces Takeda’s commitment to investing in next-generation gene therapy approaches that have the potential to deliver functional cures to patients with rare genetic and hematologic diseases.”

Additionally, Takeda will have an option to add two more programmes and is committed to providing funding for all the research and development costs for the collaboration programme.

According to the collaboration deal, Poseida will receive $45m in upfront payment from Takeda.

If the milestones for six programmes are achieved, the company will also receive preclinical milestones which could be more than $125m in total.

Additionally, it will be eligible for preclinical, development, regulatory and commercial milestone payments of up to $2.7bn for six programmes and up to $3.6bn on achieving milestones that are related to the two programmes.

Furthermore, Poseida will lead research activities of the therapy programmes up to candidate selection while Takeda will be responsible for the development as well as commercialisation.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology